Key Developments: StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

1.16USD
3:02pm EDT
Price Change (% chg)

-- (+0.00%)
Prev Close
$1.16
Open
$1.17
Day's High
$1.18
Day's Low
$1.16
Volume
35,544
Avg. Vol
99,642
52-wk High
$2.42
52-wk Low
$1.02

Search Stocks

Latest Key Developments (Source: Significant Developments)

StemCells Inc initiates phase II clinical trial in Cervical Spinal Cord Injury
Tuesday, 7 Oct 2014 08:00am EDT 

StemCells Inc:Says it has initiated its Pathway Study, a Phase II proof of concept clinical trial using its HuCNS-SC platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI).Says the trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).Says the primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders.Says the trial will follow the patients for one year from the time of enrollment.  Full Article

StemCells Inc announces closing of $20 mln offering
Friday, 18 Jul 2014 01:40pm EDT 

StemCells Inc:Announced that it has closed its previously announced offering of common stock and short term warrants.Says it sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of about $18.7 million.Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit.Warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share.Warrants will expire at the close of business on Aug. 17, 2015.Ascendiant Capital Markets, LLC acted as financial advisor and placement agent for the offering.  Full Article

StemCells Inc announces proposed $20 mln offering
Tuesday, 15 Jul 2014 08:00am EDT 

StemCells Inc:Intent to offer and sell 11,299,435 shares of common stock and short term warrants for purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors.Subject to market and other conditions, for gross proceeds of $20 mln, before deducting placement fees and other offering expenses.Intends to use net proceeds of the offering for general corporate purposes, including working capital, product development and capital expenditures.Common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.85 of a share of common stock at an offering price of $1.77 per unit.Warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share.Warrants will expire at the close of business on the date that is 13 months from the date of issuance.Expected to close on or before July 18.Ascendiant Capital Markets, LLC is acting as financial advisor and placement agent for the offering.  Full Article

StemCells Inc announces interim results in Phase I/II Dry AMD Trial
Thursday, 19 Jun 2014 08:00am EDT 

StemCells Inc:Says interim results show improvement in visual function and slowing of disease progression in phase I/II Dry AMD Trial.Reports positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SChuman neural stem cell platform in dry age-related macular degeneration (AMD).Interim trial results show a 65 pct reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 pct reduction in the rate of GA when compared to the control eye.GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium.This degeneration is the cause of vision loss in dry AMD.  Full Article

StemCells Inc expands phase I/II spinal cord injury trial to north america
Friday, 10 Jan 2014 08:00am EST 

StemCells Inc:Says a team at the University of Calgary successfully transplanted its first subject in the company's Phase I/II clinical trial in chronic spinal cord injury, with the company's HuCNS-SC human neural stem cells.Says the ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America.Says this expansion accelerates the current trial, which should complete enrollment of the remaining three patients this quarter and pave the way for a controlled Phase II efficacy study that StemCells plans to initiate mid-year.  Full Article

StemCells Inc Appoints New Chief Financial Officer
Thursday, 14 Nov 2013 09:00am EST 

StemCells, Inc announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014. In his new role, Mr. Schiffman will be responsible for all aspects of the Company's financing activities, financial reporting and controls, corporate communications, and investor relations.  Full Article

StemCells Inc Enters Into Agreement To Acquire Patent Portfolio-Form 8-K
Wednesday, 30 Oct 2013 06:02am EDT 

StemCells Inc reported in its Form 8-K that on October 24, 2013, StemCells, Inc. (the "Company") entered into an agreement to acquire from NeuroSpheres Holdings Ltd. and NeuroSpheres Ltd. (jointly, "NeuroSpheres") a patent portfolio claiming the manufacture and proliferation of purified populations of human neural stem cells and their use (collectively, the "Weiss and Reynolds patents"). These patents include U.S. Patent Nos. 5,851,832, 6,497,872, 6,294,346, 7,101,709, 7,361,505, and 7,115,418, the six patents asserted by the Company in its patent infringement suit against Neuralstem, Inc. As consideration for the Weiss and Reynolds patents, the Company will issue 139,548 shares of unregistered common stock to NeuroSpheres Holdings Ltd. Previously, the Company and its wholly owned subsidiary had licensed the Weiss and Reynolds patents from NeuroSpheres on an exclusive worldwide basis. In connection with the patent acquisition, the Company and NeuroSpheres voluntarily terminated, effective October 24, 2013, all preexisting agreements between them concerning the Weiss and Reynolds patents, including the parties’ license agreements dated April 1, 1997 and October 30, 2000. The acquisition relieves the Company from further milestone and royalty payments owed to NeuroSpheres.  Full Article

StemCells Inc Announces Closing of $18.6 Million Public Offering
Tuesday, 8 Oct 2013 09:00am EDT 

StemCells Inc announced that it has closed its previously announced underwritten public offering of common stock and warrants. The Company sold a total of 12,845,500 units, which includes the underwriter's full over-allotment option. The Company sold the units at a public offering price of $1.45 per unit and received total proceeds, net of offering expenses, underwriting discounts and commissions, of approximately $17.3 million. Each unit sold consists of one share of common stock, par value $.01 per share, and a warrant to purchase one half share of common stock. The warrants have an exercise price of $1.80 per share, are exercisable immediately, and will expire five years from the date of issuance. Chardan Capital Markets acted as sole bookrunner for the offering and Maxim Group LLC acted as co-manager.  Full Article

StemCells Inc Receives FDA Authorization Of IND For Spinal Cord Injury
Wednesday, 2 Oct 2013 09:00am EDT 

StemCells Inc announced that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application for clinical testing of the Company's HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the Company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.  Full Article

StemCells Inc Announces Pricing Of Public Offering To Raise $16.2 Million
Wednesday, 2 Oct 2013 08:14am EDT 

StemCells Inc announced the pricing of an underwritten public offering of an aggregate of 11,170,000 units at a public offering price of $1.45 per unit. Each unit consists of one share of common stock, par value $.01 per share, and a warrant to purchase one half share of common stock. The warrants have an exercise price of $1.80 per share, are exercisable immediately, and will expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $16.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30 day option to purchase up to an additional 1,675,500 units to cover over allotments, if any. The offering is expected to close on or about October 7, 2013. Chardan Capital Markets is acting as sole bookrunner for the offering and Maxim Group LLC is acting as co-manager on the deal. StemCells intends to use the net proceeds of the offering for general corporate purposes, including working capital and operational purposes, including product development.  Full Article

Search Stocks